ATI RN
ATI Pharmacology Exam 2 Questions
Extract:
Question 1 of 5
A nurse is caring for a client who has acute respiratory distress syndrome (ARDS) and requires mechanical ventilation. The client receives a prescription for pancuronium. The nurse recognizes that this medication is for which of the following purposes?
Correct Answer: A
Rationale: Pancuronium, a neuromuscular blocker, suppresses respiratory effort to optimize mechanical ventilation in ARDS, unlike compliance, secretions, or sedation.
Question 2 of 5
A nurse is caring for a client who has a new prescription for propranolol. The nurse should monitor the client for which of the following severe reactions to this medication?
Correct Answer: D
Rationale: Propranolol can cause postural hypotension by reducing vascular tone, leading to dizziness or falls, unlike ototoxicity, hypokalemia, or tachycardia.
Question 3 of 5
A nurse is assessing a client who has hypercholesterolemia and is receiving simvastatin. Which of the following findings should the nurse recognize as a potential adverse effect?
Correct Answer: D
Rationale: Simvastatin can cause muscle weakness, indicating potential rhabdomyolysis, a serious adverse effect. Blurred vision, hypotension, and urinary retention are not typical side effects.
Question 4 of 5
A nurse is caring for a client who has developed agranulocytosis as a result of taking propylthiouracil to treat hyperthyroidism. The nurse should understand that this client is at increased risk for which of the following conditions?
Correct Answer: A
Rationale: Agranulocytosis reduces white blood cells, increasing infection risk, unlike bleeding, hyperglycemia, or ecchymosis, which are not directly related.
Question 5 of 5
A nurse on an oncology unit is preparing to administer doxorubicin to a client who has breast cancer. Prior to beginning the infusion, the nurse verifies the client's current cumulative lifetime dose of the medication. For which of the following reasons is this verification necessary?
Correct Answer: C
Rationale: Excessive doxorubicin causes cardiomyopathy, a dose-dependent risk, requiring lifetime dose monitoring, unlike extravasation, urine color, or myelosuppression.